ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
uniQure NV

uniQure NV (QURE)

15.67
-0.16
(-1.01%)
마감 27 1월 6:00AM
15.80
0.13
(0.83%)
시간외 거래: 9:59AM

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
15.80
매수가
13.28
매도가
15.80
거래량
570,475
15.42 일간 변동폭 16.045
3.73 52주 범위 19.18
market_cap
전일 종가
15.83
개장가
15.83
최근 거래 시간
3000
@
15.8
(formt)
마지막 거래 시간
재정 규모
US$ 8,973,107
VWAP
15.7292
평균 볼륨(3m)
2,388,990
발행 주식
48,743,140
배당수익률
-
주가수익률
-2.48
주당순이익(EPS)
-6.33
매출
21.9M
순이익
-308.48M

uniQure NV 정보

uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipel... uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
본부
Amsterdam, North Holland, Nld
설립됨
-
uniQure NV is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker QURE. The last closing price for uniQure NV was US$15.83. Over the last year, uniQure NV shares have traded in a share price range of US$ 3.73 to US$ 19.18.

uniQure NV currently has 48,743,140 shares in issue. The market capitalisation of uniQure NV is US$771.60 million. uniQure NV has a price to earnings ratio (PE ratio) of -2.48.

QURE 최신 뉴스

uniQure Announces Pricing of its Public Offering

LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...

uniQure Announces Proposed Public Offering

LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
11.6411.58192090414.161613.786483414.68140237CS
4-1.78-10.125142207117.5819.1813.044128477215.82424574CS
1210172.4137931035.819.185.35238899014.00861538CS
267.93100.7623888187.8719.184.45141559411.92997259CS
529.86165.9932659935.9419.183.7316509269.28487612CS
156-1.91-10.784867306617.7128.2553.73107948711.77976169CS
260-46.83-74.772473255662.6371.453.7384263118.15250149CS

QURE - Frequently Asked Questions (FAQ)

What is the current uniQure NV share price?
The current share price of uniQure NV is US$ 15.80
How many uniQure NV shares are in issue?
uniQure NV has 48,743,140 shares in issue
What is the market cap of uniQure NV?
The market capitalisation of uniQure NV is USD 771.6M
What is the 1 year trading range for uniQure NV share price?
uniQure NV has traded in the range of US$ 3.73 to US$ 19.18 during the past year
What is the PE ratio of uniQure NV?
The price to earnings ratio of uniQure NV is -2.48
What is the cash to sales ratio of uniQure NV?
The cash to sales ratio of uniQure NV is 34.88
What is the reporting currency for uniQure NV?
uniQure NV reports financial results in USD
What is the latest annual turnover for uniQure NV?
The latest annual turnover of uniQure NV is USD 21.9M
What is the latest annual profit for uniQure NV?
The latest annual profit of uniQure NV is USD -308.48M
What is the registered address of uniQure NV?
The registered address for uniQure NV is PAASHEUVELWEG 25A, AMSTERDAM, NORTH HOLLAND, 1105 BP
What is the uniQure NV website address?
The website address for uniQure NV is www.uniqure.com
Which industry sector does uniQure NV operate in?
uniQure NV operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
EVAXEvaxion Biotech AS
US$ 5.99
(64.56%)
55.41M
ELABPMGC Holdings Inc
US$ 3.0901
(56.07%)
76.48M
PCLAPicoCELA Inc
US$ 4.60
(49.35%)
3.75M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
GODNUGolden Star Acquisition Corporation
US$ 3.11
(-75.82%)
17.51k
GODNGolden Star Acquisition Corporation
US$ 2.93
(-65.67%)
902.76k
NXTTNext Technology Holding Inc
US$ 1.37
(-54.93%)
2.56M
SGLYSingularity Future Technology Ltd
US$ 1.625
(-38.45%)
917.77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90.11
(-38.07%)
8
ACONAclarion Inc
US$ 0.0557
(28.94%)
811.91M
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
RIMEAlgorhythm Holdings Inc
US$ 0.0357
(4.69%)
284.97M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
NVDANVIDIA Corporation
US$ 142.62
(-3.12%)
232.88M

QURE Discussion

게시물 보기
PonkenPlonken PonkenPlonken 1 월 전
dont like throwing the term around but this has buyout written all over
super strong up here

Novartis for AMT-130 Huntington program?
👍️0
tw0122 tw0122 2 월 전
$15.72 + 113% time to exit all hard time breaking $15.78 resistance which would have led to $17s
👍️0
tw0122 tw0122 2 월 전
$15.35 + 103%
👍️0
PonkenPlonken PonkenPlonken 2 월 전
rock n roll
👍️0
tw0122 tw0122 2 월 전
$13.71 + 88%
👍️0
PonkenPlonken PonkenPlonken 2 월 전
Never before data and 11$ in cash held back by ex stock broker CEO Matt Kapusta. Is too busy milking shareholders vs advancing trials.
but dont worry, he wont make it go kaput.
👍️0
PonkenPlonken PonkenPlonken 2 월 전
Never before data and 11$ in cash held back by ex stock broker CEO Matt Kapusta. Is too busy milking shareholders vs advancing trials.
but dont worry, he wont make it go kaput.
👍️0
PonkenPlonken PonkenPlonken 3 월 전
turnaround in the making
👍️0
PonkenPlonken PonkenPlonken 3 월 전
Here it comes
Still 11$ in cash and super science. Held back by blood leech Ex-Wallstreet CEO... BP wont care
👍️0
Biggiee Biggiee 3 월 전
Get in or don’t. It’s time
$QURE
👍️0
PonkenPlonken PonkenPlonken 4 월 전
Everyone forgot about this as they are much to busy chasing the next ultra risky 10% flip.
SOOO undervalued. Suppressed by bored traders and gamblers leaving.
The data will speak again and people will realize this is worth 2-4bn.
👍️0
tbonaces80 tbonaces80 6 월 전
Buying for swing. Tier 1
👍️0
retireat40 retireat40 6 월 전
Agree until more news is released.
👍️0
Romiman Romiman 6 월 전
Got in at 5.85, I’ll be out tomorrow, this one is done.
👍️0
retireat40 retireat40 6 월 전
WTH? New LOD every time I check.
👍️0
retireat40 retireat40 6 월 전
Nope
👍️0
retireat40 retireat40 6 월 전
Turd city…
👍️0
retireat40 retireat40 6 월 전
Even less volume today than last Friday.
👍️0
retireat40 retireat40 6 월 전
Agree. Odd that it trades in the 8’s
👍️0
PonkenPlonken PonkenPlonken 6 월 전
I became an investor the second i saw the results but i also traded around my position. Ergo I am riding a free ticket now.
Company has 11$ per share in cash and the science is probably worth 2-4bn $.
👍️0
retireat40 retireat40 7 월 전
Bull or bear?
👍️0
retireat40 retireat40 7 월 전
Looked like crapola today
👍️0
tbonaces80 tbonaces80 7 월 전
Flagg forming
👍️0
PonkenPlonken PonkenPlonken 7 월 전
institutions use liquidity = take a seat and watch the scenario unfold.
👍️0
retireat40 retireat40 7 월 전
We’ll see. 80% drop in volume today.
👍️0
TechandBio TechandBio 7 월 전
UniQure Interesting move here solid pipeline added a few calls for early July for fun.
Keep an eye o Ice Cure killing cancer by cryoblation ICCM one of the most undervalued stocks.
$QURE
👍️0
tbonaces80 tbonaces80 7 월 전
Great chart. Shooting for a rip beteen $12.41-$16.75.
👍️0
PonkenPlonken PonkenPlonken 7 월 전
traders are too busy trying to make $ in silly names. Every few months there is a play like this.... that doesnt require much thinking-- only spotting it and letting the big guys do the lifting.
👍️0
PonkenPlonken PonkenPlonken 7 월 전
Listen to Victor Sung on the recent call. You dont need to be in the know to hear he hasnt seen anything similar

https://edge.media-server.com/mmc/p/m4opdukf
👍️0
Monksdream Monksdream 9 월 전
QURE under $5
👍️0
Liam859 Liam859 11 월 전
$QURE $5.14 buy it up
👍️0
MiamiGent MiamiGent 2 년 전
QURE

$26.36 +3.36 (+14.61%)
As of Nov-23-20224:00:00 PM ET

https://stockcharts.com/h-sc/ui?s=QURE

FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
BENZINGA 8:12 AM ET Nov-23-2022

UniQure N.V.'s (NASDAQ:QURE) partner CSL Limited (OTC:CSLLY) has received FDA approval for Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B.
CSL licensed the exclusive global rights to Hemgenix from uniQure in May 2021.
UniQure has received about $500 million so far from CSL and will also be eligible to get up to an additional $1.5 billion in commercial milestone payments and royalties.
Cowen analyst Joseph Thome said that Hemgenix's price of $3.5 million is higher than the brokerage's estimated $1.9 million, but its consultants have been optimistic about the therapy's uptake, Reuters reported.
Results from the pivotal HOPE-B trial support the FDA approval, the largest gene therapy trial in hemophilia B.
Results from the study demonstrated that Hemgenix allowed patients to produce mean factor IX activity of 39% at six months and 36.7% at 24 months post-infusion.
Seven to 18 months post-infusion, the mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by 54% compared to the six-month lead-in period on factor IX prophylactic replacement therapy (4.1 to 1.9).
In addition, 94% of patients treated with Hemgenix discontinued prophylaxis and remained free of previous continuous routine prophylaxis therapy.
The FDA has already cleared two gene therapies, Zynteglo and Skysona, from Bluebird bio Inc (NASDAQ: BLUE) in August and September, respectively.
👍️0
Glider549 Glider549 3 년 전
Whoops!
👍️0
ralphey ralphey 3 년 전
Insiders selling big time while biopharmcatalyst site tries to pump - noit a good sign
👍️0
Sunnycupid Sunnycupid 7 년 전
Profit taking time .. Good time to short this .. I want to be in for a short
👍️0
Thoro Thoro 7 년 전
QURE $9.15 high today, nice.
👍️0
Thoro Thoro 7 년 전
This thing is pretty volatile lately.
👍️0
Thoro Thoro 8 년 전
QURE Looked great hitting $9.00 today
👍️0
Thoro Thoro 8 년 전
QURE General Information

http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=QURE.O
👍️0
Thoro Thoro 8 년 전
Uniqure NV (QURE) Money Flow Index Nearing Key Level

http://tuckermantimes.com/uniqure-nv-qure-money-flow-index-nearing-key-level/247578/

👍️0
Thoro Thoro 8 년 전
Erratic Trading Showing Unusual Volume in Shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) and uniQure N.V. (NASDAQ:QURE)

https://www.concordregister.com/erratic-trading-showing-unusual-volume-in-shares-of-concert-pharmaceuticals-inc-nasdaqcnce-and-uniqure-n-v-nasdaqqure/

👍️0
Thoro Thoro 8 년 전
uniQure N.V. NASDAQ:QURE Sees High Volatility in Session

https://aikenadvocate.com/uniqure-n-v-nasdaqqure-sees-high-volatility-in-session/290264/
👍️0
Thoro Thoro 8 년 전
uniQure N.V. (QURE) PT Set at $13.00 by Chardan Capital

https://weekherald.com/2017/07/24/uniqure-n-v-qure-pt-set-at-13-00-by-chardan-capital.html
👍️0
Rogerthat1 Rogerthat1 8 년 전
This dog has always been a turd. Why did it run last couple days? Already see signs of rollover on today's intraday imo. $QURE
👍️0
Dutchdaan Dutchdaan 8 년 전
buying here
👍️0
Panzer Panzer 8 년 전
Lost all patience in this pos
👍️0
redsox17 redsox17 8 년 전
Patient is a virtue.
If you know what you are doing it pays off.
👍️0
jaytea jaytea 8 년 전
That's why it's down another 3%
👍️0
redsox17 redsox17 8 년 전
Trust me they are. They just don't want you to think that way.
👍️0
jaytea jaytea 8 년 전
The market does not seem to be overly impressed.
👍️0

최근 히스토리

Delayed Upgrade Clock